Biomarin Pharmaceutical Revenue vs. Price To Earning

BMRN Stock  USD 64.26  0.81  1.28%   
Taking into consideration Biomarin Pharmaceutical's profitability measurements, Biomarin Pharmaceutical is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in December. Profitability indicators assess Biomarin Pharmaceutical's ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
1999-03-31
Previous Quarter
708.7 M
Current Value
733.9 M
Quarterly Volatility
207.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Biomarin Pharmaceutical's Days Sales Outstanding is very stable compared to the past year. As of the 25th of November 2024, Operating Cash Flow Sales Ratio is likely to grow to 0.07, while Price To Sales Ratio is likely to drop 7.11. At this time, Biomarin Pharmaceutical's Interest Income is very stable compared to the past year. As of the 25th of November 2024, Net Interest Income is likely to grow to about 35.8 M, though Accumulated Other Comprehensive Income is likely to grow to (36.7 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.010.7872
Significantly Up
Slightly volatile
For Biomarin Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biomarin Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biomarin Pharmaceutical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biomarin Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biomarin Pharmaceutical over time as well as its relative position and ranking within its peers.
  

Biomarin Pharmaceutical's Revenue Breakdown by Earning Segment

Check out Trending Equities.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.607
Earnings Share
1.66
Revenue Per Share
14.529
Quarterly Revenue Growth
0.283
Return On Assets
0.03
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Biomarin Pharmaceutical Price To Earning vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Biomarin Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Biomarin Pharmaceutical value to that of its competitors to determine the firm's financial worth.
Biomarin Pharmaceutical is rated second in revenue category among its peers. It also is rated second in price to earning category among its peers . The ratio of Revenue to Price To Earning for Biomarin Pharmaceutical is about  10,960,114 . At this time, Biomarin Pharmaceutical's Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biomarin Pharmaceutical's earnings, one of the primary drivers of an investment's value.

Biomarin Pharmaceutical's Earnings Breakdown by Geography

Biomarin Revenue vs. Competition

Biomarin Pharmaceutical is rated second in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 16.12 Billion. Biomarin Pharmaceutical retains roughly 2.42 Billion in revenue claiming about 15% of equities under Health Care industry.

Biomarin Price To Earning vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Biomarin Pharmaceutical

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
2.42 B
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Biomarin Pharmaceutical

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
220.73 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Biomarin Price To Earning Comparison

Biomarin Pharmaceutical is currently under evaluation in price to earning category among its peers.

Biomarin Pharmaceutical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Biomarin Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Biomarin Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Biomarin Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Biomarin Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-38.6 M-36.7 M
Operating Income194.4 M204.2 M
Income Before Tax188.6 M198 M
Total Other Income Expense Net-5.9 M-6.2 M
Net Income167.6 M176 M
Income Tax Expense20.9 M22 M
Net Income Applicable To Common Shares162.8 M170.9 M
Net Income From Continuing Ops147 M154.4 M
Non Operating Income Net Other12.1 M7.1 M
Interest Income49 M51.5 M
Net Interest Income34.1 M35.8 M
Change To Netincome25.9 M27.2 M
Net Income Per Share 0.89  0.94 
Income Quality 0.95  1.00 
Net Income Per E B T 0.89  0.93 

Biomarin Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Biomarin Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Biomarin Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Biomarin Pharmaceutical's important profitability drivers and their relationship over time.

Use Biomarin Pharmaceutical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Biomarin Pharmaceutical Pair Trading

Biomarin Pharmaceutical Pair Trading Analysis

The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Biomarin Pharmaceutical position

In addition to having Biomarin Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Automobiles and Trucks Thematic Idea Now

Automobiles and Trucks
Automobiles and Trucks Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Automobiles and Trucks theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Automobiles and Trucks Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out Trending Equities.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
To fully project Biomarin Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Biomarin Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Biomarin Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.
Potential Biomarin Pharmaceutical investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Biomarin Pharmaceutical investors may work on each financial statement separately, they are all related. The changes in Biomarin Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biomarin Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.